TargetMol

Acumapimod

Product Code:
 
TAR-T7367
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T7367-1mg1mg£98.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7367-2mg2mg£109.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7367-5mg5mg£135.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7367-1mL1 mL * 10 mM (in DMSO)£142.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7367-10mg10mg£168.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7367-25mg25mg£230.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7367-50mg50mg£367.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7367-100mg100mg£511.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Acumapimod is an orally active inhibitor of p38α MAPK (IC50 <1 μM).
CAS:
836683-15-9
Formula:
C22H19N5O2
Molecular Weight:
385.427
Pathway:
MAPK; Autophagy
Purity:
0.98
SMILES:
Cc1ccc(cc1-n1ncc(C(=O)c2cccc(c2)C#N)c1N)C(=O)NC1CC1
Target:
p38 MAPK; Autophagy

References

Growcott E J , Bamba D , Galarneau J . R , et al. The effect of P38 MAP kinase inhibition in a mouse model of influenza[J]. Journal of Medical Microbiology, 2018, 67(3). De Buck S , Hueber W , Vitaliti A , et al. Population PK-PD Model for Tolerance Evaluation to the p38 MAP Kinase Inhibitor BCT197[J]. CPT: Pharmacometrics & Systems Pharmacology, 2015, 4(12):691-700.